- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05554913
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
September 21, 2022 updated by: Qilu Pharmaceutical Co., Ltd.
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Thrombopoietin Mimetic Peptide-Fc Fusion Protein for Injection (QL0911) in the Prevention of Chemotherapy- Induced Thrombocytopenia
To evaluate the efficacy and safety of QL0911 to prevention chemotherapy-induced thrombocytopenia.
Thrombocytopenia is a low number of platelets in the blood.
Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
For the phase III study, a double-blind randomized, placebo controlled, parallel-group design will be conducted to evaluate the efficacy and safety of QL0911 .
Each subject will be randomly assigned to either Arm A (QL0911) or Arm B (placebo) in 2:1 ratio.The primary objective is to compare the effective rates of the two treatment arms.
The study will consist of a screening period of up to 4 weeks, a treatment period of 2 planned cycles of chemotherapy, a follow-up visit of 2 weeks.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jin Li
- Phone Number: 13761222111
- Email: tianyoulijin@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200120
- Recruiting
- Shanghai East Hospital
-
Contact:
- Jin Li
- Phone Number: 021-38804518
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged ≥18 years old;
- Histopathological or cytological examination confirmed solid tumor or lymphoma (including NSCLC, breast cancer, bladder cancer, pancreatic cancer, etc.), chemotherapy cycle of 21 days, and using of one or more of the following chemotherapy drugs: gemcitabine; Platinum, including carboplatin, nedaplatin, cisplatin, lobaplatin, etc.; Anthracyclines, including doxorubicin, daunorubicin, epirubicin, etc.; Taxa, including paclitaxel, docetaxel, etc.
- Previous chemotherapy regiments ≤3 lines;
- The current chemotherapy regimen should be consistent with that of the previous chemotherapy cycle, including the chemotherapy drugs and the dosages, without adding or subtracting drugs or dosages;
- Occurred chemotherapy delay by CIT in the current chemotherapy regimen or platelet <75×10^9/L at the end of the chemotherapy cycle (21d±3 days) before enrollment;
- At least two platelet counts with an interval of more than 24 hours in the chemotherapy cycle before enrollment was grade 2 or higher thrombocytopenia;
- The platelet count was between 75×10^9/L-150×10^9/L (including both ends) 1 day before chemotherapy or the day of Randomization;
- At the time of screening, the expected survival time is ≥12 weeks, and the current chemotherapy regimen can be accepted for at least 2 cycles;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;
- Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form.
Exclusion Criteria:
- Suffering from other hematopoietic system diseases besides lymphoma, including leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma and myelodysplastic syndromes, etc.
- Have experienced thrombocytopenia caused by non-tumor chemotherapeutics within 6 months before screening,Including, but not limited to, EDTA-dependent pseudothrombocytopenia, hypersplenism, infection, and bleeding, etc.
- Brain tumors, brain metastases,bone marrow invasion or bone marrow metastasis;
- Receiving radiotherapy or have received abdominal pelvic or sternum radiotherapy within 3 months;
- Any arterial or venous thrombosis occurred within 6 months before screening;
- Severe cardiovascular disease (e.g., NYHA Heart Function Score Class III-IV), arrhythmias such as atrial fibrillation that increase the risk of thrombosis, coronary stenting, angioplasty, and coronary artery bypass grafting within the previous 6 months were screened;
- Clinical manifestations of severe bleeding (such as gastrointestinal bleeding, etc.) within 4 weeks before the first administration of the experimental drug;
- Received platelet transfusion within 5 days before randomization/enrollment;
- Received thrombopoietin receptor agonist treatment within 4 weeks, human recombinant thrombopoietin (rhTPO) or rhIL-11 within 4 weeks,other Chinese medicines with the effect of raising blood plate within 1 week before the administration of the experimental drug;
- Used heparin, warfarin, aspirin and other anticoagulant drugs within 7 days before the first dose except for the purpose of sealing the tube;
- Received bone marrow transplantation or stem cell infusion within 1 year before screening;
- Patients with hepatitis C antibody positive and detection of HCV-RNA exceeding the upper limit, patients with hepatitis B surface antigen positive and detection of HBV-DNA exceeding the upper limit, patients with severe cirrhosis, HIV antibody positive and syphilis antibody positive;
- The absolute value of neutrophils in the screening period<1.5×10^9/L, hemoglobin <90g/L;
- Total bilirubin greater than 3X ULN; alanine aminotransferase [ALT] and aspartate aminotransferase [AST] greater than 3X ULN for subjects without liver metastases or greater than or equal to 5X ULN for subjects with liver metastases during screening;
- Serum creatinine concentration ≥1.5ULN or eGFR≤60ml/min (cockcroft-gault);
- Severe drug allergic reactions;
- Used any investigational drug within 3 months before the administration of the experimental drug;
- Planning pregnancy, pregnancy, or suckling period;
- The investigator judged that the patients are not suitable for participating in this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: QL0911
The study in a 2:1 randomization ratio(40 subjects to QL0911).
Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
|
This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
|
Placebo Comparator: Placebo
The study in a 2:1 randomization ratio(20 subjects to Placebo ).
Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
|
Placebo comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients who had an efficacy response during the double-blind period
Time Frame: 42 days
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lowest and highest platelet count
Time Frame: 42 days
|
42 days
|
Bleeding score(Revised WHO grading system)
Time Frame: 42 days
|
42 days
|
Proportion of patients with platelet count < 50×10^9/L per cycle
Time Frame: 42 days
|
42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2022
Primary Completion (Anticipated)
May 1, 2023
Study Completion (Anticipated)
July 1, 2023
Study Registration Dates
First Submitted
September 18, 2022
First Submitted That Met QC Criteria
September 21, 2022
First Posted (Actual)
September 26, 2022
Study Record Updates
Last Update Posted (Actual)
September 26, 2022
Last Update Submitted That Met QC Criteria
September 21, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QL0911-CIT-301(Part B)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-induced Thrombocytopenia
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingChemotherapy-Induced Thrombocytopenia
-
Sobi, Inc.CompletedChemotherapy-induced ThrombocytopeniaUnited States, China, Hungary, Poland, Russian Federation, Serbia, Ukraine
-
Beijing Northland Biotech. Co., Ltd.CompletedChemotherapy-induced ThrombocytopeniaChina
-
BioMAS LtdTerminatedChemotherapy Induced ThrombocytopeniaIsrael
-
Qilu Pharmaceutical Co., Ltd.CompletedChemotherapy-induced ThrombocytopeniaChina
-
Napolitano MariasantaRegione SiciliaTerminatedThrombocytopenia | Primary Thrombocytopenia,Unspecified | Thrombocytopenia Chemotherapy InducedItaly
-
Jiangsu HengRui Medicine Co., Ltd.Withdrawn
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingChemotherapy-Induced ThrombocytopeniaChina
-
Ono Pharma USA IncTerminatedChemotherapy-Induced ThrombocytopeniaUnited States, Korea, Republic of, Russian Federation
-
Institute of Hematology & Blood Diseases HospitalHenan Cancer Hospital; Tianjin Medical University Cancer Institute and Hospital and other collaboratorsRecruitingChemotherapy-induced Thrombocytopenia | HerombopagChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States